* Cue Biopharma Inc reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of five analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -22 cents to -17 cents per share.

* Revenue rose 58.9% to $3.34 million from a year ago; analysts expected $1.52 million.

* Cue Biopharma Inc's reported EPS for the quarter was a loss of 17 cents​.

* The company reported a quarterly loss of $8.66 million.

* Cue Biopharma Inc shares had risen by 98.1% this quarter and lost 43.2% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 21.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Cue Biopharma Inc is $4.00 This summary was machine generated from LSEG data November 15 at 02:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.19 -0.17 Beat

Jun. 30 2024 -0.28 -0.20 Beat

Mar. 31 2024 -0.28 -0.25 Beat

Dec. 31 2023 -0.28 -0.29 Missed